Global Pharmaceutical Contract Manufacturing Market Report 2022: Growing Need for State-Of-The-Art Processes and Production Technologies Driving Sector - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Pharmaceutical Contract Manufacturing Market Research and Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.

The global market for pharmaceutical contract manufacturing is projected to have a considerable CAGR of around 6.9% during the forecast period. All pharmaceutical companies operate as outsourcing companies, dealing with the development and manufacturing of drugs, which leads to business scalability and revenue, which allows for the development of new drugs. The growing need for state-of-the-art processes and production technologies, which have proven highly effective in meeting regulatory requirements, is the most important factor driving the growth of CMOs in the pharmaceutical industry.

The increasing number of cell therapy candidates, combined with their steady growth through the various stages of clinical development and their complicated manufacturing process, drives up demand for manufacturing services for these therapies. Therefore, this factor creates an opportunity for market growth. However, the dynamic changes seen in this sector, combined with extreme margin pressure, are expected to restrict growth significantly.

Segmental Outlook

The global pharmaceutical contract manufacturing market is segmented based on category, type, product and service. Based on the category the market is further classified into human-based drugs and animals-based drugs. On the basis of type, the market is further segregated into sterile manufacturing and non-sterile manufacturing. Further on the basis of product, the market is classified into over-the-counter (OTC) drugs, active pharmaceutical ingredients (API), finished dosage formulation and others (nutritional products and packaging) and based on services the market is segmented into manufacturing services, non-clinical services, and research & development.

Global Pharmaceutical Contract Manufacturing Market to be driven by active pharmaceutical ingredients (API).

Among products, the active pharmaceutical ingredients (API), the segment is projected to hold a considerable share in the market owing to factors such as the rising prevalence of chronic diseases including cardiovascular diseases and cancer and increasing advancements in active pharmaceutical ingredient (API) manufacturing. The API segment is experiencing significant changes as a result of the supply chain disruption caused by COVID-19.

Due to geopolitical situations and the desire to reduce dependence on China for API products, countries such as India are being preferred over China for API export. Furthermore, pharmaceutical firms benefit from API production outsourcing because it eliminates the need for costly manufacturing unit installation and labor force. However, unfavorable drug pricing policies in various countries, as well as high manufacturing costs, are expected to restrain the segment growth.

The Report Covers

• Market value data analysis of 2020 and forecast to 2027.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global Pharmaceutical Contract Manufacturing market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market entry and market expansion strategies.
• Competitive strategies by identifying 'who-stands-where' in the market.

Key Topics Covered:

1. Report Summary

2. Market Overview and Insights

3. Competitive Landscape

4. Market Determinants

5. Market Segmentation

6. Regional Analysis

7. Company Profiles

Companies Mentioned

• Aenova Holding GmbH
• Ajinomoto Co., Inc.
• Almac Group Ltd.
• Amgen Inc.
• Aurobindo Pharma Ltd.
• Baxter International Inc.
• BDR Pharmaceuticals International Pvt. Ltd.
• BiologicsMD, Inc.
• Boehringer Ingelheim International GmbH
• Cadence Inc. *List not exhaustive

For more information about this report visit https://www.researchandmarkets.com/r/mn7gme

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900